Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060258 | 0.86 | OPRM1 (0.36) | OPRM1OPRK1OPRL1HTR2ASIGMAR1 | |
| SCHEMBL15468333 | 0.83 | HTR2A (0.40) | OPRM1OPRK1OPRL1HTR2AHTR2C | |
| SCHEMBL10060259 | 0.73 | XIAP (0.39) | OPRM1OPRK1 | |
| SCHEMBL10079282 | 0.69 | XIAP (0.36) | OPRM1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL12771389 | 0.68 | PIK3CD (0.38) | OPRM1OPRK1OPRL1 | |
| SCHEMBL12771380 | 0.68 | PIK3CD (0.38) | OPRM1OPRK1OPRL1 | |
| SCHEMBL14170111 | 0.68 | BRD4 (0.38) | OPRM1HTR2AHTR2CHTR2BPRCP | |
| SCHEMBL4737427 | 0.67 | XIAP (0.48) | HTR2AHTR2CHTR2B | |
| SCHEMBL10060256 | 0.67 | PRCP (0.38) | OPRM1HTR2AHTR2CHTR2BPRCP | |
| SCHEMBL15468334 | 0.67 | PRCP (0.38) | OPRM1HTR2AHTR2CHTR2BPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | OPRM1 4489/4885OPRK1 4094/4885OPRL1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.